Development of Diagnostic and Therapeutic Probes with Controlled Pharmacokinetics for Use in Radiotheranostics
The word “theranostics,” a portmanteau word made by combining “therapeutics” and “diagnostics,” refers to a personalized medicine concept. Recently, the word, “radiotheranostics,” has also been used in nuclear medicine as a term that refer to the use of radioisotopes for combined imaging and therapy...
Gespeichert in:
| Veröffentlicht in: | Chemical & pharmaceutical bulletin 2019/09/01, Vol.67(9), pp.897-903 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 903 |
|---|---|
| container_issue | 9 |
| container_start_page | 897 |
| container_title | Chemical & pharmaceutical bulletin |
| container_volume | 67 |
| creator | Ogawa, Kazuma |
| description | The word “theranostics,” a portmanteau word made by combining “therapeutics” and “diagnostics,” refers to a personalized medicine concept. Recently, the word, “radiotheranostics,” has also been used in nuclear medicine as a term that refer to the use of radioisotopes for combined imaging and therapy. For radiotheranostics, a diagnostic probe and a corresponding therapeutic probe can be prepared by introducing diagnostic and therapeutic radioisotopes into the same precursor. These diagnostic and therapeutic probes can be designed to show equivalent pharmacokinetics, which is important for radiotheranostics. As imaging can predict the absorbed radiation dose and thus the therapeutic and side effects, radiotheranostics can help achieve the goal of personalized medicine. In this review, I discuss the use of radiolabeled probes targeting bone metastases, sigma-1 receptor, and αVβ3 integrin for radiotheranostics. |
| doi_str_mv | 10.1248/cpb.c19-00274 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2294027528</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2294027528</sourcerecordid><originalsourceid>FETCH-LOGICAL-c510t-ded5c85a82908e9448ec0416777f465afcbb216c213ac4cf79c73eb431dff8a63</originalsourceid><addsrcrecordid>eNpFkFtLwzAYQIMobl4efZWAz9Xc2rSPMq8wUESfQ5p-2Tq7pCad4r83c3O-JIQczsd3EDqj5JIyUV6Zvr40tMoIYVLsoTHlQmY5Y3wfjQkhVcZ4wUfoKMZFQnIi-SEacSqkkKwYI3cDn9D5fgluwN7im1bPnI9Da7B2DX6dQ9A9rNbv5-BriPirHeZ44t0QfNdBg5_nOiy18e-tg4RFbH3AbxFw6_CLblo_rB0bZzxBB1Z3EU639zF6u7t9nTxk06f7x8n1NDM5JUPWQJObMtclq0gJlRAlGCJoIaW0osi1NXXNaGEY5doIY2VlJIdacNpYW-qCH6OLjbcP_mMFcVALvwoujVSMVSK1ylmZqGxDmeBjDGBVH9qlDt-KErWuq1Jdleqq37qJP99aV_USmh39lzMBkw2wiIOewQ7QIS3fwa-ukKpaHzvt_28qqcDxHx4Pj5s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2294027528</pqid></control><display><type>article</type><title>Development of Diagnostic and Therapeutic Probes with Controlled Pharmacokinetics for Use in Radiotheranostics</title><source>J-STAGE Free</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Ogawa, Kazuma</creator><creatorcontrib>Ogawa, Kazuma</creatorcontrib><description>The word “theranostics,” a portmanteau word made by combining “therapeutics” and “diagnostics,” refers to a personalized medicine concept. Recently, the word, “radiotheranostics,” has also been used in nuclear medicine as a term that refer to the use of radioisotopes for combined imaging and therapy. For radiotheranostics, a diagnostic probe and a corresponding therapeutic probe can be prepared by introducing diagnostic and therapeutic radioisotopes into the same precursor. These diagnostic and therapeutic probes can be designed to show equivalent pharmacokinetics, which is important for radiotheranostics. As imaging can predict the absorbed radiation dose and thus the therapeutic and side effects, radiotheranostics can help achieve the goal of personalized medicine. In this review, I discuss the use of radiolabeled probes targeting bone metastases, sigma-1 receptor, and αVβ3 integrin for radiotheranostics.</description><identifier>ISSN: 0009-2363</identifier><identifier>EISSN: 1347-5223</identifier><identifier>DOI: 10.1248/cpb.c19-00274</identifier><identifier>PMID: 31474726</identifier><language>eng</language><publisher>Japan: The Pharmaceutical Society of Japan</publisher><subject>Animals ; arginine-glycine-aspartic acid (RGD) peptide ; bone metastasis ; Bone Neoplasms - diagnosis ; Bone Neoplasms - diagnostic imaging ; Bone Neoplasms - radiotherapy ; cancer ; Contrast Media - chemistry ; Contrast Media - metabolism ; Diagnostic systems ; Humans ; imaging ; Medical imaging ; Metastases ; Nuclear medicine ; Oligopeptides - chemistry ; Oligopeptides - metabolism ; Oligopeptides - therapeutic use ; Pharmacokinetics ; Pharmacology ; Precision medicine ; Probes ; Radiation ; Radiation dosage ; Radioisotopes ; radionuclide therapy ; Radiopharmaceuticals - chemistry ; Radiopharmaceuticals - pharmacokinetics ; Radiopharmaceuticals - therapeutic use ; radiotheranostics ; Receptors, sigma - chemistry ; Receptors, sigma - metabolism ; Side effects ; Sigma-1 Receptor ; Single Photon Emission Computed Tomography Computed Tomography ; Tissue Distribution</subject><ispartof>Chemical and Pharmaceutical Bulletin, 2019/09/01, Vol.67(9), pp.897-903</ispartof><rights>2019 The Pharmaceutical Society of Japan</rights><rights>Copyright Japan Science and Technology Agency 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c510t-ded5c85a82908e9448ec0416777f465afcbb216c213ac4cf79c73eb431dff8a63</citedby><cites>FETCH-LOGICAL-c510t-ded5c85a82908e9448ec0416777f465afcbb216c213ac4cf79c73eb431dff8a63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31474726$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ogawa, Kazuma</creatorcontrib><title>Development of Diagnostic and Therapeutic Probes with Controlled Pharmacokinetics for Use in Radiotheranostics</title><title>Chemical & pharmaceutical bulletin</title><addtitle>Chem. Pharm. Bull.</addtitle><description>The word “theranostics,” a portmanteau word made by combining “therapeutics” and “diagnostics,” refers to a personalized medicine concept. Recently, the word, “radiotheranostics,” has also been used in nuclear medicine as a term that refer to the use of radioisotopes for combined imaging and therapy. For radiotheranostics, a diagnostic probe and a corresponding therapeutic probe can be prepared by introducing diagnostic and therapeutic radioisotopes into the same precursor. These diagnostic and therapeutic probes can be designed to show equivalent pharmacokinetics, which is important for radiotheranostics. As imaging can predict the absorbed radiation dose and thus the therapeutic and side effects, radiotheranostics can help achieve the goal of personalized medicine. In this review, I discuss the use of radiolabeled probes targeting bone metastases, sigma-1 receptor, and αVβ3 integrin for radiotheranostics.</description><subject>Animals</subject><subject>arginine-glycine-aspartic acid (RGD) peptide</subject><subject>bone metastasis</subject><subject>Bone Neoplasms - diagnosis</subject><subject>Bone Neoplasms - diagnostic imaging</subject><subject>Bone Neoplasms - radiotherapy</subject><subject>cancer</subject><subject>Contrast Media - chemistry</subject><subject>Contrast Media - metabolism</subject><subject>Diagnostic systems</subject><subject>Humans</subject><subject>imaging</subject><subject>Medical imaging</subject><subject>Metastases</subject><subject>Nuclear medicine</subject><subject>Oligopeptides - chemistry</subject><subject>Oligopeptides - metabolism</subject><subject>Oligopeptides - therapeutic use</subject><subject>Pharmacokinetics</subject><subject>Pharmacology</subject><subject>Precision medicine</subject><subject>Probes</subject><subject>Radiation</subject><subject>Radiation dosage</subject><subject>Radioisotopes</subject><subject>radionuclide therapy</subject><subject>Radiopharmaceuticals - chemistry</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Radiopharmaceuticals - therapeutic use</subject><subject>radiotheranostics</subject><subject>Receptors, sigma - chemistry</subject><subject>Receptors, sigma - metabolism</subject><subject>Side effects</subject><subject>Sigma-1 Receptor</subject><subject>Single Photon Emission Computed Tomography Computed Tomography</subject><subject>Tissue Distribution</subject><issn>0009-2363</issn><issn>1347-5223</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkFtLwzAYQIMobl4efZWAz9Xc2rSPMq8wUESfQ5p-2Tq7pCad4r83c3O-JIQczsd3EDqj5JIyUV6Zvr40tMoIYVLsoTHlQmY5Y3wfjQkhVcZ4wUfoKMZFQnIi-SEacSqkkKwYI3cDn9D5fgluwN7im1bPnI9Da7B2DX6dQ9A9rNbv5-BriPirHeZ44t0QfNdBg5_nOiy18e-tg4RFbH3AbxFw6_CLblo_rB0bZzxBB1Z3EU639zF6u7t9nTxk06f7x8n1NDM5JUPWQJObMtclq0gJlRAlGCJoIaW0osi1NXXNaGEY5doIY2VlJIdacNpYW-qCH6OLjbcP_mMFcVALvwoujVSMVSK1ylmZqGxDmeBjDGBVH9qlDt-KErWuq1Jdleqq37qJP99aV_USmh39lzMBkw2wiIOewQ7QIS3fwa-ukKpaHzvt_28qqcDxHx4Pj5s</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Ogawa, Kazuma</creator><general>The Pharmaceutical Society of Japan</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20190901</creationdate><title>Development of Diagnostic and Therapeutic Probes with Controlled Pharmacokinetics for Use in Radiotheranostics</title><author>Ogawa, Kazuma</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c510t-ded5c85a82908e9448ec0416777f465afcbb216c213ac4cf79c73eb431dff8a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>arginine-glycine-aspartic acid (RGD) peptide</topic><topic>bone metastasis</topic><topic>Bone Neoplasms - diagnosis</topic><topic>Bone Neoplasms - diagnostic imaging</topic><topic>Bone Neoplasms - radiotherapy</topic><topic>cancer</topic><topic>Contrast Media - chemistry</topic><topic>Contrast Media - metabolism</topic><topic>Diagnostic systems</topic><topic>Humans</topic><topic>imaging</topic><topic>Medical imaging</topic><topic>Metastases</topic><topic>Nuclear medicine</topic><topic>Oligopeptides - chemistry</topic><topic>Oligopeptides - metabolism</topic><topic>Oligopeptides - therapeutic use</topic><topic>Pharmacokinetics</topic><topic>Pharmacology</topic><topic>Precision medicine</topic><topic>Probes</topic><topic>Radiation</topic><topic>Radiation dosage</topic><topic>Radioisotopes</topic><topic>radionuclide therapy</topic><topic>Radiopharmaceuticals - chemistry</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Radiopharmaceuticals - therapeutic use</topic><topic>radiotheranostics</topic><topic>Receptors, sigma - chemistry</topic><topic>Receptors, sigma - metabolism</topic><topic>Side effects</topic><topic>Sigma-1 Receptor</topic><topic>Single Photon Emission Computed Tomography Computed Tomography</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ogawa, Kazuma</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Chemical & pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ogawa, Kazuma</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Diagnostic and Therapeutic Probes with Controlled Pharmacokinetics for Use in Radiotheranostics</atitle><jtitle>Chemical & pharmaceutical bulletin</jtitle><addtitle>Chem. Pharm. Bull.</addtitle><date>2019-09-01</date><risdate>2019</risdate><volume>67</volume><issue>9</issue><spage>897</spage><epage>903</epage><pages>897-903</pages><issn>0009-2363</issn><eissn>1347-5223</eissn><abstract>The word “theranostics,” a portmanteau word made by combining “therapeutics” and “diagnostics,” refers to a personalized medicine concept. Recently, the word, “radiotheranostics,” has also been used in nuclear medicine as a term that refer to the use of radioisotopes for combined imaging and therapy. For radiotheranostics, a diagnostic probe and a corresponding therapeutic probe can be prepared by introducing diagnostic and therapeutic radioisotopes into the same precursor. These diagnostic and therapeutic probes can be designed to show equivalent pharmacokinetics, which is important for radiotheranostics. As imaging can predict the absorbed radiation dose and thus the therapeutic and side effects, radiotheranostics can help achieve the goal of personalized medicine. In this review, I discuss the use of radiolabeled probes targeting bone metastases, sigma-1 receptor, and αVβ3 integrin for radiotheranostics.</abstract><cop>Japan</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>31474726</pmid><doi>10.1248/cpb.c19-00274</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-2363 |
| ispartof | Chemical and Pharmaceutical Bulletin, 2019/09/01, Vol.67(9), pp.897-903 |
| issn | 0009-2363 1347-5223 |
| language | eng |
| recordid | cdi_proquest_journals_2294027528 |
| source | J-STAGE Free; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Free Full-Text Journals in Chemistry |
| subjects | Animals arginine-glycine-aspartic acid (RGD) peptide bone metastasis Bone Neoplasms - diagnosis Bone Neoplasms - diagnostic imaging Bone Neoplasms - radiotherapy cancer Contrast Media - chemistry Contrast Media - metabolism Diagnostic systems Humans imaging Medical imaging Metastases Nuclear medicine Oligopeptides - chemistry Oligopeptides - metabolism Oligopeptides - therapeutic use Pharmacokinetics Pharmacology Precision medicine Probes Radiation Radiation dosage Radioisotopes radionuclide therapy Radiopharmaceuticals - chemistry Radiopharmaceuticals - pharmacokinetics Radiopharmaceuticals - therapeutic use radiotheranostics Receptors, sigma - chemistry Receptors, sigma - metabolism Side effects Sigma-1 Receptor Single Photon Emission Computed Tomography Computed Tomography Tissue Distribution |
| title | Development of Diagnostic and Therapeutic Probes with Controlled Pharmacokinetics for Use in Radiotheranostics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T17%3A33%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Diagnostic%20and%20Therapeutic%20Probes%20with%20Controlled%20Pharmacokinetics%20for%20Use%20in%20Radiotheranostics&rft.jtitle=Chemical%20&%20pharmaceutical%20bulletin&rft.au=Ogawa,%20Kazuma&rft.date=2019-09-01&rft.volume=67&rft.issue=9&rft.spage=897&rft.epage=903&rft.pages=897-903&rft.issn=0009-2363&rft.eissn=1347-5223&rft_id=info:doi/10.1248/cpb.c19-00274&rft_dat=%3Cproquest_cross%3E2294027528%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2294027528&rft_id=info:pmid/31474726&rfr_iscdi=true |